Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: sprucebiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2025 | $160.00 | Market Perform → Outperform | Leerink Partners |
| 10/28/2025 | $254.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 12/11/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 12/11/2024 | Outperform → Perform | Oppenheimer | |
| 3/14/2024 | Buy → Neutral | Guggenheim | |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/14/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 3/14/2024 | Buy → Neutral | H.C. Wainwright | |
| 2/21/2024 | $10.00 | Buy | Guggenheim |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
424B3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
EFFECT - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
EFFECT - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
S-3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
S-3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
D - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
Fastest customizable press release news feed in the world
Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for the Treatment of MPS IIIB on Track for the First Quarter of 2026 Completed $50.0 Million Private Placement Financing Backed by Dedicated Healthcare Investors Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2025 and provided corporate updates. "We ha
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses, to advance tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) through a biologics license application submission in the first quarter of 2026 and potential U.S. commercial launch in late 2026. The private placement
Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE) U.S. FDA Confirmed that CSF HS-NRE is a Surrogate Biomarker Reasonably Likely to Predict Clinical Benefit and Could Serve as Basis for Accelerated Approval Biologics License Application Submission of TA-ERT for MPS IIIB Remains on Track for the First Quarter of 2026 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that the U.S. Food and Drug A
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol "SPRB" and CUSIP 85209E 208. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube. View source version on busin
Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for MPS IIIB Anticipated in First Quarter of 2026 First Patient Dosed in Phase 2 TAMARIND Trial of Tildacerfont for Major Depressive Disorder (MDD) with Topline Results Anticipated in 1H 2026 Nasdaq Capital Market Relisting Anticipated Following Compliance with Minimum Bid Price for 20 Consecutive Trading Days Spruce Biosciences, Inc. (OTCQB:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel
TA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in MPS IIIB U.S. FDA Confirmed that CSF HS-NRE is a Surrogate Biomarker Reasonably Likely to Predict Clinical Benefit and Could Serve as Basis for Accelerated Approval Cognition and Cortical Grey Matter Volume Were Stabilized in Patients Treated with TA-ERT Relative to Declines Observed in Untreated Patients Spruce Biosciences, Inc. (OTCQB:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced results from a
Spruce's Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following Compliance with Minimum Bid Price for 20 Consecutive Trading Days Spruce Biosciences, Inc. (OTCQB:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it will implement a 1-for-75 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on August 4, 2025. The Reverse Stock Split was approved by the company's stockholders at its Annual
Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC"), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that the first patient has been dosed in the Phase 2 clinical trial called "Tildacerfont as Antidepressant Medicatio
Relisting Contingent Upon Stockholder Approval of Reverse Stock Split Trading on Nasdaq Capital Market Anticipated to Commence On or Before August 5, 2025 Spruce Biosciences, Inc. (OTC:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC ("Nasdaq") to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or before August 5, 2025. "We are pleased by Nasdaq's decision to lift its trading suspensio
Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026 Spruce Biosciences, Inc. (OTC:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. "With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by t
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00
Citizens JMP upgraded Spruce Biosciences from Mkt Perform to Mkt Outperform and set a new price target of $254.00
JMP Securities downgraded Spruce Biosciences from Mkt Outperform to Mkt Perform
Oppenheimer downgraded Spruce Biosciences from Outperform to Perform
Guggenheim downgraded Spruce Biosciences from Buy to Neutral
Leerink Partners downgraded Spruce Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $9.00 previously
RBC Capital Mkts downgraded Spruce Biosciences from Outperform to Sector Perform and set a new price target of $2.00 from $9.00 previously
Ladenburg Thalmann downgraded Spruce Biosciences from Buy to Neutral
H.C. Wainwright downgraded Spruce Biosciences from Buy to Neutral
Guggenheim initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $10.00
Live finance-specific insights
Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci
Live Leadership Updates
Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and
CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro
CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates. "The third quarter of 2022 was one of continuous execution and momentum on multiple fronts. We were pleased to have recently surpassed 25% enrollment in our CAHmelia-204 study and are approaching 50% enrollment in our C
Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of Tildacerfont Patent Portfolio Estate with Key Method of Use Patents Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates. "Throughout the second quarter of 2022, we continued to remain focused on clinical study execution. We were pleased to have recently s
25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Million Credit Line in 2022 Tildacerfont Patent Portfolio Estate Expanded with Key Method of Use Patents Libbie Mansell, Ph.D., M.B.A., R.A.C., Appointed Chief Regulatory and Quality Officer Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates. "Throughout
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy. "Dr. Mansell brings extensive regulatory affairs and quality expertise at precisely the right time for Spruce, as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary synd
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company's clinical development and global drug development strategy. "We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leade
– Samir Gharib, MBA, Promoted to President – Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer. "With his range of leadership and demonstrated success in rare disease drug development, Javier is an excellent fit for Spruce Biosciences as we enter the next chapter of clinical develop
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Mike Grey as interim Chief Executive Officer, effective immediately. Mr. Grey currently serves as Executive Chairman of the Spruce Board, and will succeed Richard King, who is retiring after a 35-year career in the life sciences industry. Mr. King will remain a strategic advisor to the company through December 31, 2021. Spruce's Board will initiate a candidate search to identify a permanent Chief Executive Officer. "On behalf of the entire Board, I want to
This live feed shows all institutional transactions in real time.
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13D/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)